Healthcare Sales & Marketing Network News: VX-950

Searching News Database: VX-950

HSMN NewsFeed - 2 Nov 2007
First Studies Demonstrating Greater than Sixty Percent Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients
Biopharmaceuticals

HSMN NewsFeed - 30 Jun 2006
Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 23 May 2006
Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naive HCV Patients
Biopharmaceuticals

HSMN NewsFeed - 22 May 2006
Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients
Biopharmaceuticals

HSMN NewsFeed - 29 Apr 2006
New Oral Polymerase Inhibitor Shows Promising Results in Chronic Hepatitis C Patients
Biopharmaceuticals

HSMN NewsFeed - 7 Feb 2006
Vertex Successfully Completes Key Studies with VX-950 to Prepare for Next Steps in Clinical Program
Biopharmaceuticals

Return to NewsFeed

Additional items found! 10

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 10 additional stories matching:
VX-950
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.